GICS Sector : Healthcare
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis.
In the fourth quarter of 2025, Eton Pharmaceuticals reported revenue of $21.3 million, an 83% jump YoY, and adjusted EBITDA of $6.2 million, equating to a 29% margin—up from 18% in 2024. GAAP net income was a modest $1.5 million, while non‑GAAP net income reached $5.4 million, reflecting a $0.05 EPS versus analyst expectations of $0.12.
Publication Date: 07:13
The lift was driven by the successful launch of Incrolex, Galzyn, and Kinduvi, with Alkindi Sprinkle adding a new revenue stream. Product revenue alone hit $21.3 million, underscoring the strength of Eton’s pediatric endocrinology portfolio and the momentum behind Desmota, the newly FDA‑approved oral desmopressin, which is expected to generate $30 M to $50 M in peak sales (Staff, 2025).
Adjusted gross profit climbed to $15.5 million, a 73% margin—up from 59% last year—thanks to higher product mix and efficient cost controls. R&D outlays rose to $1.8 million, while G&A increased to $8.9 million; however, the company’s disciplined spending has still yielded a 29% EBITDA margin, a notable improvement over the 18% in 2024.
Beyond the existing lineup, the company is advancing key pipeline assets: Hemangiol’s relaunch, the extended‑release Galzin (ET700), and the planned NDA for AMCLIDIA by year‑end. With 300 active Galzin patients and a projected 800‑patient base, the pipeline is poised to double patient numbers and generate over $100 million in peak sales for ET700.
Eton’s cash flow conversion from EBITDA is projected to remain positive in 2026, with operating cash flow expected to cover debt principal repayments. The acquisition of Hemangiol was financed entirely from cash on hand, avoiding dilution and keeping net debt/EBITDA at a favorable negative 4.36.
At a P/S ratio of 8.55 and an EV/EBITDA of 174.16, the stock trades at a premium that reflects its rapid growth trajectory and high‑margin prospects. The company’s goal of a $200 million revenue run‑rate by Q4 2027 and a 50% adjusted EBITDA margin by 2028 underscores the potential for further upside.
Eton Pharmaceuticals Inc (ETON) Shares Fall 9.4% -- What GF Score of 73 Tells Investors
Apr -16
Eton Pharmaceuticals Announces CFO Succession Plan
Apr -16
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Mar -24
Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why
Mar -23
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
Mar -20
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
Mar -19
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Mar -19
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Mar -19
Eton Pharmaceuticals' 8.74% growth in Prescription Drug Products is driven by increasing demand for specialty generics, expanded product offerings, and strategic partnerships. Additionally, the company's focus on rare disease treatments and orphan drugs contributes to growth. Furthermore, investments in R&D and regulatory approvals for new products also support the segment's growth.
Alkindi Sprinkle is a hydrocortisone granule formulation for the treatment of adrenocortical insufficiency in pediatric patients.
Biorphen is a phenylephrine injection used to treat clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
Rezipres is a prescription medicine used to treat high blood pressure in adults and children 6 years of age and older.
ET-105 is a novel, oral, once-daily formulation of topiramate for the treatment of epilepsy and other central nervous system disorders.
Eton Pharmaceuticals, Inc. faces moderate threat from substitutes due to the presence of alternative treatments and generic drugs.
Customers have limited bargaining power due to the specialized nature of Eton Pharmaceuticals, Inc.'s products and the lack of alternative suppliers.
Suppliers have moderate bargaining power due to the presence of multiple suppliers and the company's dependence on a few key suppliers.
The threat of new entrants is high due to the growing demand for pharmaceuticals and the relatively low barriers to entry in the industry.
The intensity of rivalry is high due to the presence of several established players in the industry and the high stakes involved in the development of new drugs.
| Value | |
|---|---|
| Debt Weight | 26.06% |
| Debt Cost | 6.79% |
| Equity Weight | 73.94% |
| Equity Cost | 9.88% |
| WACC | 9.07% |
| Leverage | 35.25% |
Value: 7.4
Growth: 7.9
Quality: 7.0
Yield: 0.0
Momentum: 6.0
Volatility: 1.0
1-Year Total Return ->
Value: 4.5
Growth: 7.2
Quality: 3.0
Yield: 0.0
Momentum: 9.0
Volatility: 3.0
1-Year Total Return ->
Value: 7.8
Growth: 4.8
Quality: 3.0
Yield: 0.0
Momentum: 6.5
Volatility: 3.7
1-Year Total Return ->
Value: 9.6
Growth: 5.6
Quality: 5.1
Yield: 0.0
Momentum: 0.5
Volatility: 1.7
1-Year Total Return ->
Value: 8.8
Growth: 3.4
Quality: 5.2
Yield: 0.0
Momentum: 0.0
Volatility: 0.3
1-Year Total Return ->
Value: 6.8
Growth: 2.9
Quality: 2.6
Yield: 0.0
Momentum: 0.5
Volatility: 0.7
1-Year Total Return ->